Alnylam Pharmaceuticals (ALNY) Stock Falls As Q3 Earnings Lean On Tax Gain

Alnylam Pharmaceuticals walked into this Q3 2026 report with the stock already under pressure, down roughly 33% over the past month and another 5% today to about US$165. The headline result was anything but soft. Reported net income for the quarter jumped to US$2.17b, driven largely by a very large non cash tax benefit that turned an already profitable rare disease specialist into a statistical outlier.

Short term traders saw red on the screen, while long term holders are likely focused on what this kind of earnings mix and a P/E near 8x might mean for the next several years of RNA interference driven growth, risk and valuation.

Love the rare disease exposure and RNAi story at Alnylam Pharmaceuticals but uneasy about an earnings line dominated by a one off tax gain and a compressed P/E? Compare this setup with a curated group of high quality businesses on our list of solid balance sheet and fundamentals stocks (25 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$1,458.1m vs. US$1,249.0m (higher quarter on quarter and year on year)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$2,167.3m vs. US$251.1m (very large increase, driven mainly by a non‑cash tax benefit)
• Basic EPS (Q3 2026 vs. Q3 2025): US$16.19 vs. US$1.91 (very large jump, reflecting the non‑cash tax gain in net income)
• TTR Franchise Product Revenue (Q3 2026 vs. Q3 2025): ~US$1.15b vs. prior year level (management cited 59% year on year growth in TTR)

AMVUTTRA reach is surging, but patient starts are lagging. Ask Charlie what Alnylam isn’t saying about AMVUTTRA’s demand gap.

Alnylam pipeline story meets early execution tests

The bullish pitch rests on RNAi breadth turning into multiple commercial pillars beyond TTR. That ambition is spelled out clearly.

"The broad RNAi portfolio at Alnylam Pharmaceuticals, with more than 25 programs across rare, specialty and prevalent conditions and multiple pivotal studies underway, creates repeated opportunities for new approvals that could add incremental revenue streams and help spread fixed R&D and SG&A over a larger sales base, which may support earnings."

Q3 shows both progress and friction. Strong TTR product revenue and growing Huntington’s and hypertension programs support the multi asset goal, yet R&D and SG&A rose faster than non GAAP operating income, so the margin benefit is not visible yet.

TTR dependence and spending risks stay in focus

Bears worry that high costs and TTR reliance could choke the Alnylam Pharmaceuticals story if newer programs underperform.

"Sustained high levels of R&D and SG&A spending to support pipeline development and expand commercial operations, including large cardiovascular outcomes trials and new AI or manufacturing investments, could exceed top line growth if new RNAi programs in hypertension and other prevalent diseases do not achieve commercial success."

That concern finds support in this quarter. TTR contributed the vast majority of product revenue, non GAAP operating income fell 11% even with strong sales, and management now guides TTR toward the low end of the 2026 range while keeping spending elevated.

One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all.

Hunt For Mispriced Earnings Power

Alnylam Pharmaceuticals just showed how headline earnings and stock moves can tell very different stories. The real opportunity could be finding stocks where fundamentals and expectations quietly diverge before the gap closes.

• Company 1 - 34% below our estimate - turn long term optical and solar contracts and customer prepayments into higher margin infrastructure glass and photonics sales.
• Company 2 - 42% below our estimate - sell integrated server and storage stacks that large AI buyers now prefer over piecemeal hardware configurations.
• Company 3 - 48% below our estimate - convert a record backlog of complex data center and modular projects into recurring high value building services work.

That is three of the list. See every one of the 29 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com